Revolution Medicines Presents Pancreatic Cancer Survival Data at ESMO 2026
Revolution Medicines presented overall survival data for daraxonrasib across subgroups in previously treated metastatic pancreatic cancer at ESMO 2026.
Revolution Medicines presented overall survival data for daraxonrasib across subgroups in previously treated metastatic pancreatic cancer at ESMO 2026.